Simpson D R, Browett P J, Doak P B, Palmer S J
Department of Haematology, Auckland Hospital, New Zealand.
Bone Marrow Transplant. 1994 Oct;14(4):635-6.
There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately severe VOD complicated by anuria following an allogeneic bone marrow transplant for relapsed acute myeloid leukaemia. Following initiation of peritoneal dialysis she received tPA at a dose of 10 mg/day for 5 days. There was rapid improvement in her urine output and liver function with no bleeding complications. This case suggests that the requirement of dialysis may not preclude the use of tPA in established VOD and therefore warrants further study.
已有关于重组组织型纤溶酶原激活剂(tPA)用于已确诊的静脉闭塞性疾病(VOD)的令人鼓舞的报道。鉴于潜在的止血并发症,血液透析一直被视为该疗法的禁忌证。我们报告一例女性患者,她在接受异基因骨髓移植治疗复发的急性髓系白血病后发生了中度严重的VOD并伴有无尿。在开始腹膜透析后,她接受了剂量为每日10毫克的tPA治疗,持续5天。她的尿量和肝功能迅速改善,且无出血并发症。该病例表明,透析需求可能并不排除在已确诊的VOD中使用tPA,因此值得进一步研究。